Epigallocatechin Gallate (EGCG) Improves Anti-Angiogenic State, Cell Viability, and Hypoxia-Induced Endothelial Dysfunction by Downregulating High Mobility Group Box 1 (HMGB1) in Preeclampsia

Overview

Journal Med Sci Monit

Specialties General Medicine
Pathology

Date 2020 Oct 15

PMID 33056943

Citations 6

Authors

Min Zhong

Julan Peng

Lanhua Xiang

Xinhuang Yang

Xianghua Wang

Yanbin Zhu

Affiliations

Soon will be listed here.

Abstract

BACKGROUND Preeclampsia (PE) is a serious complication of pregnancy with no effective therapy. This study assessed whether epigallocatechin gallate (EGCG) could reduce the production of anti-angiogenic factors, improve cell viability, and suppress endothelial dysfunction in vitro via regulating high mobility group box 1 (HMGB1) in preeclampsia. MATERIAL AND METHODS Human umbilical vein endothelial cells (HUVECs) grown in conditioned medium from hypoxic JEG-3 cells were used to investigate the effects of EGCG on anti-angiogenic state, cell viability, and markers of endothelial dysfunction. To confirm that EGCG exerted its effects via HMGB1, we also examined the impact of EGCG on anti-angiogenic state, cell viability, and endothelial dysfunction following HMGB1 treatment in vitro. RESULTS EGCG inhibited HMGB1 expression in hypoxic trophoblast cells in a dose-dependent manner. In addition, EGCG relieved anti-angiogenic state and endothelial dysfunction in hypoxic trophoblast cells by downregulating HMGB1. Moreover, EGCG dose-dependently promoted cell proliferation by downregulating HMGB1. CONCLUSIONS Taken together, our data show the protective role of EGCG in preeclampsia and revealed EGCG-mediated effects on the production of anti-angiogenic factors, cell viability, and endothelial dysfunction through downregulating HMGB1. These observations suggest that EGCG is a novel therapeutic candidate for preeclampsia.

Citing Articles

EGCG, a Green Tea Compound, Increases NO Production and Has Antioxidant Action in a Static and Shear Stress In Vitro Model of Preeclampsia.

Bertozzi-Matheus M, Bueno-Pereira T, Nunes P, Sandrim V Antioxidants (Basel). 2024; 13(2).

PMID: 38397756 PMC: 10886151. DOI: 10.3390/antiox13020158.

HMGB1: a double-edged sword and therapeutic target in the female reproductive system.

Ren Y, Zhu D, Han X, Zhang Q, Chen B, Zhou P Front Immunol. 2023; 14:1238785.

PMID: 37691930 PMC: 10484633. DOI: 10.3389/fimmu.2023.1238785.

Effects of Antioxidant Intake on Fetal Development and Maternal/Neonatal Health during Pregnancy.

Sebastiani G, Navarro-Tapia E, Almeida-Toledano L, Serra-Delgado M, Paltrinieri A, Garcia-Algar O Antioxidants (Basel). 2022; 11(4).

PMID: 35453333 PMC: 9028185. DOI: 10.3390/antiox11040648.

The Efficacy Mechanism of Epigallocatechin Gallate against Pre-Eclampsia based on Network Pharmacology and Molecular Docking.

Gao X, Wang J, Shi J, Sun Q, Jia N, Li H Reprod Sci. 2022; 29(6):1859-1873.

PMID: 35211881 DOI: 10.1007/s43032-022-00894-2.

Inhibition of HMGB1 Ameliorates the Maternal-Fetal Interface Destruction in Unexplained Recurrent Spontaneous Abortion by Suppressing Pyroptosis Activation.

Zhu D, Zou H, Liu J, Wang J, Ma C, Yin J Front Immunol. 2022; 12:782792.

PMID: 35003098 PMC: 8732860. DOI: 10.3389/fimmu.2021.782792.

References

Wiseman S, Marlborough F, Doubal F, Webb D, Wardlaw J . Blood markers of coagulation, fibrinolysis, endothelial dysfunction and inflammation in lacunar stroke versus non-lacunar stroke and non-stroke: systematic review and meta-analysis. Cerebrovasc Dis. 2014; 37(1):64-75. DOI: 10.1159/000356789. View

Trapiella-Alfonso L, Alexandre L, Fraichard C, Pons K, Dumas S, Huart L . VEGF (Vascular Endothelial Growth Factor) Functionalized Magnetic Beads in a Microfluidic Device to Improve the Angiogenic Balance in Preeclampsia. Hypertension. 2019; 74(1):145-153. DOI: 10.1161/HYPERTENSIONAHA.118.12380. View

Yang G, Wang Z, Bai F, Qin X, Cao J, Lv J . Epigallocatechin-3-gallate protects HUVECs from PM2.5-induced oxidative stress injury by activating critical antioxidant pathways. Molecules. 2015; 20(4):6626-39. PMC: 6272777. DOI: 10.3390/molecules20046626. View

Sava R, March K, Pepine C . Hypertension in pregnancy: Taking cues from pathophysiology for clinical practice. Clin Cardiol. 2018; 41(2):220-227. PMC: 6490052. DOI: 10.1002/clc.22892. View

Katusic Z, Austin S . Neurovascular Protective Function of Endothelial Nitric Oxide　- Recent Advances. Circ J. 2016; 80(7):1499-503. DOI: 10.1253/circj.CJ-16-0423. View

Mori A, Nishi H, Sasaki T, Nagamitsu Y, Kawaguchi R, Okamoto A . HLA-G expression is regulated by miR-365 in trophoblasts under hypoxic conditions. Placenta. 2016; 45:37-41. DOI: 10.1016/j.placenta.2016.07.004. View

Hu Y, Yan R, Zhang C, Zhou Z, Liu M, Wang C . High-Mobility Group Box 1 From Hypoxic Trophoblasts Promotes Endothelial Microparticle Production and Thrombophilia in Preeclampsia. Arterioscler Thromb Vasc Biol. 2018; 38(6):1381-1391. PMC: 5970057. DOI: 10.1161/ATVBAHA.118.310940. View

. ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. Obstet Gynecol. 2018; 133(1):1. DOI: 10.1097/AOG.0000000000003018. View

Churchill D, Duley L, Thornton J, Moussa M, Ali H, Walker K . Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks' gestation. Cochrane Database Syst Rev. 2018; 10:CD003106. PMC: 6517196. DOI: 10.1002/14651858.CD003106.pub3. View

10.

Alasztics B, Kukor Z, Panczel Z, Valent S . [The pathophysiology of preeclampsia in view of the two-stage model]. Orv Hetil. 2012; 153(30):1167-76. DOI: 10.1556/OH.2012.29415. View

11.

Rahnemaei F, Abbasi Fashami M, Abdi F, Abbasi M . Factors effective in the prevention of Preeclampsia:A systematic review. Taiwan J Obstet Gynecol. 2020; 59(2):173-182. DOI: 10.1016/j.tjog.2020.01.002. View

12.

Li Q, Han Y, Xu P, Yin L, Si Y, Zhang C . Elevated microRNA-125b inhibits cytotrophoblast invasion and impairs endothelial cell function in preeclampsia. Cell Death Discov. 2020; 6:35. PMC: 7220944. DOI: 10.1038/s41420-020-0269-0. View

13.

Yang B, Gao P, Wu X, Yu J, Li Y, Meng R . Epigallocatechin-3-gallate attenuates neointimal hyperplasia in a rat model of carotid artery injury by inhibition of high mobility group box 1 expression. Exp Ther Med. 2017; 14(3):1975-1982. PMC: 5609174. DOI: 10.3892/etm.2017.4774. View

14.

Maria Bellussi L, Cocca S, Chen L, Passali F, Sarafoleanu C, Passali D . Rhinosinusal Inflammation and High Mobility Group Box 1 Protein: A New Target for Therapy. ORL J Otorhinolaryngol Relat Spec. 2016; 78(2):77-85. DOI: 10.1159/000443481. View

15.

Shi D, Guo J, Zhou L, Wang N . Epigallocatechin gallate enhances treatment efficacy of oral nifedipine against pregnancy-induced severe pre-eclampsia: A double-blind, randomized and placebo-controlled clinical study. J Clin Pharm Ther. 2017; 43(1):21-25. DOI: 10.1111/jcpt.12597. View

16.

Zhao Y, Vanhoutte P, Leung S . Vascular nitric oxide: Beyond eNOS. J Pharmacol Sci. 2015; 129(2):83-94. DOI: 10.1016/j.jphs.2015.09.002. View

17.

Khambu B, Yan S, Huda N, Yin X . Role of High-Mobility Group Box-1 in Liver Pathogenesis. Int J Mol Sci. 2019; 20(21). PMC: 6862281. DOI: 10.3390/ijms20215314. View

18.

Jiang R, Cai J, Zhu Z, Chen D, Wang J, Wang Q . Hypoxic trophoblast HMGB1 induces endothelial cell hyperpermeability via the TRL-4/caveolin-1 pathway. J Immunol. 2014; 193(10):5000-12. DOI: 10.4049/jimmunol.1303445. View

19.

Chae Y, Kim C, Ha T, Hescheler J, Ahn H, Sachinidis A . Epigallocatechin-3-O-gallate inhibits the angiotensin II-induced adhesion molecule expression in human umbilical vein endothelial cell via inhibition of MAPK pathways. Cell Physiol Biochem. 2007; 20(6):859-66. DOI: 10.1159/000110446. View

20.

Sharifi-Rad M, Pezzani R, Redaelli M, Zorzan M, Imran M, Khalil A . Preclinical Pharmacological Activities of Epigallocatechin-3-gallate in Signaling Pathways: An Update on Cancer. Molecules. 2020; 25(3). PMC: 7037968. DOI: 10.3390/molecules25030467. View